Posted On: 12/30/2014 5:07:46 PM
Post# of 98241
I have rarely seen great top line results
for a pharma not pop that day.
$NDRM
NeuroDerm Announces Topline Results
of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
for a pharma not pop that day.
$NDRM
NeuroDerm Announces Topline Results
of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
(0)
(0)Scroll down for more posts ▼
